Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to 32.23%.

  • Iradimed's EBIT Margin rose 6400.0% to 32.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.87%, marking a year-over-year increase of 9600.0%. This contributed to the annual value of 29.99% for FY2024, which is 5700.0% down from last year.
  • According to the latest figures from Q3 2025, Iradimed's EBIT Margin is 32.23%, which was up 6400.0% from 33.26% recorded in Q2 2025.
  • Over the past 5 years, Iradimed's EBIT Margin peaked at 35.78% during Q3 2023, and registered a low of 18.8% during Q2 2021.
  • In the last 5 years, Iradimed's EBIT Margin had a median value of 29.57% in 2023 and averaged 28.68%.
  • As far as peak fluctuations go, Iradimed's EBIT Margin soared by 619100bps in 2021, and later plummeted by -41900bps in 2024.
  • Quarter analysis of 5 years shows Iradimed's EBIT Margin stood at 26.19% in 2021, then increased by 9bps to 28.62% in 2022, then increased by 3bps to 29.57% in 2023, then grew by 1bps to 29.91% in 2024, then grew by 8bps to 32.23% in 2025.
  • Its EBIT Margin stands at 32.23% for Q3 2025, versus 33.26% for Q2 2025 and 27.84% for Q1 2025.